1. Enhancing aortic valve drug delivery with PAR2-targeting magnetic nano-cargoes for calcification alleviation
- Author
-
Jinyong Chen, Tanchen Ren, Lan Xie, Haochang Hu, Xu Li, Miribani Maitusong, Xuhao Zhou, Wangxing Hu, Dilin Xu, Yi Qian, Si Cheng, Kaixiang Yu, Jian`an Wang, and Xianbao Liu
- Subjects
Science - Abstract
Abstract Calcific aortic valve disease is a prevalent cardiovascular disease with no available drugs capable of effectively preventing its progression. Hence, an efficient drug delivery system could serve as a valuable tool in drug screening and potentially enhance therapeutic efficacy. However, due to the rapid blood flow rate associated with aortic valve stenosis and the lack of specific markers, achieving targeted drug delivery for calcific aortic valve disease has proved to be challenging. Here we find that protease-activated-receptor 2 (PAR2) expression is up-regulated on the plasma membrane of osteogenically differentiated valvular interstitial cells. Accordingly, we develop a magnetic nanocarrier functionalized with PAR2-targeting hexapeptide for dual-active targeting drug delivery. We show that the nanocarriers effectively deliver XCT790—an anti-calcification drug—to the calcified aortic valve under extra magnetic field navigation. We demonstrate that the nano-cargoes consequently inhibit the osteogenic differentiation of valvular interstitial cells, and alleviate aortic valve calcification and stenosis in a high-fat diet-fed low-density lipoprotein receptor-deficient (Ldlr −/−) mouse model. This work combining PAR2- and magnetic-targeting presents an effective targeted drug delivery system for treating calcific aortic valve disease in a murine model, promising future clinical translation.
- Published
- 2024
- Full Text
- View/download PDF